Investigational drug · Phase 3
BIVV001
Also called: efanesoctocog, Altuvoct, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein, rFVIIIFc-VWF-XTEN
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
12
Any phase or sponsor naming "BIVV001"
First trial start
2021
Feb 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BIVV001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Haemophilia A (Moderate or Severe)
- Hemophilia A
- Hemophilia A, Severe
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BIVV001" as an intervention, largest first.
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia APivotal-lookingActive, not recruiting
Bioverativ, a Sanofi companySanofi (SNY)
NCT04644575 · 261 participants · Start Feb 23, 2021 · Primary completion Jan 15, 2027
Drug: efanesoctocog alfa (BIVV001) · For: Hemophilia A
Sites: Los Angeles, California; San Diego, California; Gainesville, Florida · 85 sites in all
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia AActive, not recruiting
SanofiSanofi (SNY)
NCT05911763 · 200 participants (planned) · Start Jun 30, 2023 · Primary completion Jun 6, 2028
Drug: Efanesoctocog Alfa BIVV001 · For: Hemophilia A
Sites: Gilbert, Arizona; Loma Linda, California; Los Angeles, California · 28 sites in all
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia APivotal-lookingCompleted
Bioverativ, a Sanofi companySanofi (SNY)
NCT04161495 · 159 participants · Start Nov 19, 2019 · Primary completion Feb 3, 2022
Drug: efanesoctocog alfa (BIVV001) · For: Factor VIII Deficiency
Sites: Los Angeles, California; San Diego, California; Gainesville, Florida · 47 sites in all
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT05817812 · 93 participants · Start Jul 31, 2023 · Primary completion Jun 2, 2026
Drug: Efanesoctocog alfa · For: Hemophilia A, Severe
Sites: Vienna, Austria; Zagreb, Croatia; Brno, Czechia · 30 sites in all
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaPivotal-lookingActive, not recruiting
Swedish Orphan BiovitrumIndustry
NCT06716814 · 89 participants · Start Mar 6, 2025 · Primary completion Mar 2027
Drug: Efanesoctocog alfa · For: Haemophilia A (Moderate or Severe)
Sites: Plovdiv, Bulgaria; Sofia, Bulgaria; Brest, France · 20 sites in all
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanActive, not recruiting
SanofiSanofi (SNY)
NCT06684314 · 79 participants · Start Nov 11, 2024 · Primary completion Aug 28, 2031
Drug: Efanesoctocog alfa · For: Hemophilia A
Sites: Changhua, Taiwan; Kaohsiung City, Taiwan; New Taipei City, Taiwan · 10 sites in all
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia APivotal-lookingCompleted
Bioverativ, a Sanofi companySanofi (SNY)
NCT04759131 · 74 participants · Start Feb 19, 2021 · Primary completion Jan 18, 2023
Drug: efanesoctocog alfa (BIVV001) · For: Hemophilia A
Sites: Los Angeles, California; Gainesville, Florida; Atlanta, Georgia · 40 sites in all
SanofiSanofi (SNY)
NCT06941870 · 35 participants (planned) · Start Sep 23, 2025 · Primary completion Oct 25, 2027
Drug: Efanesoctocog alfa · For: Factor VIII Deficiency
Sites: Los Angeles, California; Sacramento, California; Indianapolis, Indiana · 19 sites in all
Swedish Orphan BiovitrumIndustry
NCT06579144 · 24 participants · Start Feb 24, 2025 · Primary completion May 21, 2026
Drug: Efanesoctocog alfa · For: Hemophilia A
Sites: Sofia, Bulgaria; Bonn, Germany; Frankfurt, Germany · 7 sites in all
Bioverativ, a Sanofi companySanofi (SNY)
NCT03205163 · 16 participants · Start Aug 28, 2017 · Primary completion Nov 12, 2018
Drug: Advate (Low Dose); Advate (High Dose) and 2 more · For: Hemophilia A
Sites: Los Angeles, California; Indianapolis, Indiana; Iowa City, Iowa · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial.
Spasov E, Quon D, Fukutake K, et al. · Curr Ther Res Clin Exp 2026
- Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa.
Rauch A, Maynadié H, Desage S, et al. · Blood Adv 2026
- Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series.
Ashraf A, Kuhlman R, Khan O, et al. · J Thromb Haemost 2026
- Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.
Malec L, Nolan B, Chan AKC, et al. · Haemophilia 2026
- The Correction Factor for Monitoring Efanesoctocog Alfa Is Not Always 2.5.
Platton S, Platton J, Kniola K, et al. · Haemophilia 2026
- Efanesoctocog Alfa for the Management of a Life-Threatening Intracranial Haemorrhage in Mild Haemophilia A: A Case Report.
Seoane LC, Fuentes PS, Diaz PS, et al. · Cureus 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.